Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-
renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor …

The purpose of this article is to review the status and limitations of anatomic tumor response
metrics including the World Health Organization (WHO) criteria, the Response Evaluation …

Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers,
including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are …

The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in
many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …

Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …

Multiple myeloma is largely incurable, despite development of therapies that target myeloma
cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells …

Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the
underlying mechanisms are poorly understood. Here, we combined high-dimensional …